Mabpharm FY26 H1 profit more than doubled to RMB 31.36 million; revenue rises 45.1% to RMB 397.94 millionPUBT·Aug 28 at 01:05 PM021810.00%
Hong Kong Market Wrap: Kaisa's Windfall and Jingrui's Liquidation Highlight Sector ExtremesGlobal Report·Aug 5 at 09:12 AM01638+2.50%021810.00%
"MABPHARM" achieved a net profit of 57.13 million RMB for the entire year, turning a loss into a profitAASTOCKS·Mar 26 at 02:27 PM021810.00%
Hong Kong Stock Movement Quick Report: QUANTGROUP surged 22.28%, FIT HON TENG and XXF rose over 10%HK Stock Alerts·Mar 18 at 04:00 AM02685+6.48%01759-1.42%
Hong Kong Stock Movement Quick Report: BRIGHT SMART and MOBVISTA surged over 20%, while DEEPEXI TECH plummeted 17%HK Stock Alerts·Mar 13 at 03:00 AM01428-0.67%01860-5.78%
Insiders the biggest winners as Mabpharm Limited's (HKG:2181) market cap rises to HK$2.3bSimplywall·Jan 10 at 12:38 AM021810.00%
MABPHARM-B: Zhang Yanyun has been appointed as the Chief Independent Non-Executive DirectorZhitong·Oct 31, 2025 at 11:10 AM021810.00%
MABPHARM's interim net profit is 2.9 million RMB, turning losses into profitsAASTOCKS·Aug 28, 2025 at 08:40 PM021810.00%
MABPHARM-B released its interim results, with a profit attributable to shareholders of HKD 2.898 million, turning from a loss to a profit year-on-yearZhitong·Aug 28, 2025 at 12:11 PM021810.00%
